Lipella Pharmaceuticals Abstract on Oral Lichen Planus Treatment Accepted for Podium Presentation at 2025 AAOM/EAOM International Meeting Conference on “Global Transformation in Oral Medicine”

Core Insights - Lipella Pharmaceuticals Inc. announced that its abstract on LP-10 for treating Oral Lichen Planus (OLP) has been accepted for presentation at the 2025 joint international meeting of the American Academy of Oral Medicine and European Association of Oral Medicine [1][2] - The study results indicate that LP-10, a liposomal formulation of tacrolimus, shows clinically meaningful improvements in patients with symptomatic OLP, including visible lesion resolution and reduced inflammation [2][3] Study Details - The Phase 2a trial is a multicenter, dose-ranging study assessing the safety, tolerability, and efficacy of LP-10 oral rinse in adults with symptomatic OLP, evaluating three dose levels: 0.25 mg, 0.5 mg, and 1.0 mg [4] - Topline findings from the 0.5 mg cohort demonstrated statistically significant improvement (p < 0.05) at the primary endpoint, with all outcome measures showing significance at Week 4 [4] Company Overview - Lipella Pharmaceuticals is a clinical-stage biotechnology company focused on developing new drugs by reformulating existing generic drugs for new applications, targeting diseases with significant unmet needs [5]